ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care

decision-making, and AST should be offered selectively rather than administered universally. FutureFuture studies should evaluate treatment patterns and realworld oncological outcomes as more mature follow-up in the era of adjuvant immune checkpoint inhibition becomes available.Data sources that distinguish between specific systemic agents and capture recurrence, comorbidity, contraindications, and patient preferences will be required to better assess treatment allocation and effectiveness.In parallel, greater awareness of guideline recommendations among treating physicians and multidisciplinary decision-making may help optimize the risk-adapted use of AST in routine clinical practice.

Authors

Institutions

Publication Details

Journal
Annals of Surgical Oncology
Published
2026-08-28
DOI
https://doi.org/10.1245/s10434-026-20472-z
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care

Maximilian Filzmayer, Yasmine Heß-Busch, Luca Carmignani, Clara Humke et al.
Annals of Surgical Oncology
Renal cell carcinoma treatment
article

ASO Author Reflections: Risk-Adapted Use of Adjuvant Systemic Therapy in Real-World Kidney Cancer Care

Maximilian Filzmayer, Yasmine Heß-Busch, Luca Carmignani, Clara Humke, Jordan A. Goyal, Michele Petix, Pierre I. Karakiewicz, Leonardo Quarta, Filippo Orlandi, Salvatore Micali, Alberto Briganti, Mike Wenzel, Shahrokh F. Shariat, Fred Saad, Felix K.-H. Chun
article en

Abstract

decision-making, and AST should be offered selectively rather than administered universally. FutureFuture studies should evaluate treatment patterns and realworld oncological outcomes as more mature follow-up in the era of adjuvant immune checkpoint inhibition becomes available.Data sources that distinguish between specific systemic agents and capture recurrence, comorbidity, contraindications, and patient preferences will be required to better assess treatment allocation and effectiveness.In parallel, greater awareness of guideline recommendations among treating physicians and multidisciplinary decision-making may help optimize the risk-adapted use of AST in routine clinical practice.

Annals of Surgical Oncology
Al-Ahliyya Amman University (JO), Goethe University Frankfurt (DE), University of Modena and Reggio Emilia (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), Cornell University (US), McGill University Health Centre (CA), Comprehensive Cancer Center Vienna (AT), IRCCS Policlinico San Donato (IT), University Hospital Frankfurt (DE), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele (IT), Université de Montréal (CA), Medical University of Vienna (AT), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 11%
Renal cell carcinoma treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.